Evidence based guidelines for the treatment of Helicobacter pylori infection in Korea 2020

• Published in: The Korean journal of internal medicine Vol. 36; no. 4; pp. 807 - 838
• Main Authors: Jung, Hye-Kyung, Kang, Seung Joo, Lee, Yong Chan, Yang, Hyo-Joon, Park, Seon-Young, Shin, Cheol Min, Kim, Sung Eun, Lim, Hyun Chul, Kim, Jie-Hyun, Nam, Su Youn, Shin, Woon Geon, Park, Jae Myung, Choi, Il Ju, Kim, Jae Gyu, Choi, Miyoung
• Format: Journal Article
• Language: English
• Published: Korean Association of Internal Medicine 01.07.2021; The Korean Association of Internal Medicine; 대한내과학회
• Subjects: Guideline; guidelines; helicobacter pylori; meta-analysis; microbial sensitivity tests; treatment; 내과학
• ISSN: 1226-3303; 2005-6648; 2005-6648
• DOI: 10.3904/kjim.2020.701

Helicobacter pylori infection is one of the most common infectious diseases worldwide. H. pylori is responsible for substantial gastrointestinal morbidity with a high disease burden. Since the revision of the H. pylori Clinical Practice Guidelines in 2013 in Korea, the eradication rate of H. pylori has gradually decreased with the use of a clarithromycin based triple therapy. According to a nationwide randomized controlled study by the Korean College of Helicobacter and Upper Gastrointestinal Research released in 2018, the intention-to-treat eradication rate was only 63.9%, which was mostly due to increased antimicrobial resistance to clarithromycin. The clinical practice guidelines for treatment of H. pylori were updated based on evidence-based medicine from a meta-analysis conducted on a target group receiving the latest level of eradication therapy. The draft recommendations developed based on the meta-analysis were finalized after expert consensus on three recommendations regarding the indication for treatment and eight recommendations on the treatment itself. These guidelines were designed to provide clinical evidence for the treatment of H. pylori to patients, nurses, medical school students, policymakers, and clinicians. These may differ from current medical insurance standards, and will be revised if more evidence emerges in the future.Helicobacter pylori infection is one of the most common infectious diseases worldwide. H. pylori is responsible for substantial gastrointestinal morbidity with a high disease burden. Since the revision of the H. pylori Clinical Practice Guidelines in 2013 in Korea, the eradication rate of H. pylori has gradually decreased with the use of a clarithromycin based triple therapy. According to a nationwide randomized controlled study by the Korean College of Helicobacter and Upper Gastrointestinal Research released in 2018, the intention-to-treat eradication rate was only 63.9%, which was mostly due to increased antimicrobial resistance to clarithromycin. The clinical practice guidelines for treatment of H. pylori were updated based on evidence-based medicine from a meta-analysis conducted on a target group receiving the latest level of eradication therapy. The draft recommendations developed based on the meta-analysis were finalized after expert consensus on three recommendations regarding the indication for treatment and eight recommendations on the treatment itself. These guidelines were designed to provide clinical evidence for the treatment of H. pylori to patients, nurses, medical school students, policymakers, and clinicians. These may differ from current medical insurance standards, and will be revised if more evidence emerges in the future.